Market Update Economic Events Directors Deals Commodities Prices News Market Movers

Shield Therapeutics iron deficiency treatment gets Swiss regulatory nod

Wednesday, 24th April 2019
Shield Therapeutics said Swiss regulators had approved an extension of the approved indication for its iron deficiency treatment to now include treatment of all adults with iron deficiency with or without anaemia.

Approval from the Swiss Agency for Therapeutic Products followed an equivalent broadening of the marketing authorisation approval for Feraccru in the European Union in 2018.

'Switzerland represents an attractive market opportunity as it is both well reimbursed and has a much higher level of treatment penetration compared to other markets, particularly for IV iron therapies,' chief executive Carl Sterritt said.

Story provided by

Related Shares: Shield Thera

Share Search
Share Search Share Search

Visit the Share Search.
Share Search

Share News
Share News will do their best to ensure the quality of the information displayed on this site, but all information is provided as-is, free of charge. We cannot be held responsible for any loss, material or otherwise, due to incorrect information found here. UK data supplied by NBTrader and Digital Look. Share Prices are at least 15 minutes delayed.